My take on the standing ovation for DESTINY Breast 04
Traztuzumab Deruxtecan vs. Investigator choice after endocrine therapy and 1 or 2 chemotherapies for HER2 low
Want to check another podcast?
Enter the RSS feed of a podcast, and see all of their public statistics.
